Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.

Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE.

Eur Urol Focus. 2018 Sep 8. pii: S2405-4569(18)30242-6. doi: 10.1016/j.euf.2018.08.023. [Epub ahead of print]

PMID:
30206003
2.

Global and targeted microRNA expression profiling in clear cell renal cell carcinoma tissues potentially links miR-155-5p and miR-210-3p to both tumorigenesis and recurrence.

Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN, Wu X.

Am J Pathol. 2018 Sep 7. pii: S0002-9440(18)30201-3. doi: 10.1016/j.ajpath.2018.07.026. [Epub ahead of print]

PMID:
30201497
3.

Conditional survival of patients with small renal masses undergoing active surveillance.

Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, Wood CG, Matin SF.

BJU Int. 2018 Jul 14. doi: 10.1111/bju.14486. [Epub ahead of print]

PMID:
30007044
4.

Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.

Sun M, Meyer CP, Karam JA, de Velasco G, Chang SL, Pal SK, Trinh QD, Choueiri TK.

Eur J Surg Oncol. 2018 Sep;44(9):1439-1445. doi: 10.1016/j.ejso.2018.05.026. Epub 2018 Jun 5.

PMID:
29935840
5.

Salvage topical therapy for upper tract urothelial carcinoma.

Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

World J Urol. 2018 May 26. doi: 10.1007/s00345-018-2349-9. [Epub ahead of print]

PMID:
29804202
6.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7.

PMID:
29748098
7.

Adjuvant therapy for advanced renal cell carcinoma.

Meissner MA, McCormick BZ, Karam JA, Wood CG.

Expert Rev Anticancer Ther. 2018 Jul;18(7):663-671. doi: 10.1080/14737140.2018.1469980. Epub 2018 May 2.

PMID:
29707987
8.

Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.

Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y.

Carcinogenesis. 2018 May 28;39(6):752-757. doi: 10.1093/carcin/bgy021.

PMID:
29635281
9.

Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes.

Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG.

Urology. 2018 Jun;116:114-119. doi: 10.1016/j.urology.2018.03.017. Epub 2018 Mar 22.

PMID:
29578041
10.

Editorial Comment.

Karam JA.

J Urol. 2018 Jun;199(6):1432. doi: 10.1016/j.juro.2017.11.154. Epub 2018 Mar 16. No abstract available.

PMID:
29555540
11.

The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus.

Hutchinson R, Rew C, Chen G, Woldu S, Krabbe LM, Meissner M, Sheth K, Singla N, Shakir N, Master VA, Karam JA, Matin SF, Borregales LD, Wood C, Masterson T, Thompson RH, Boorjian SA, Leibovich BC, Abel EJ, Bagrodia A, Margulis V.

Urology. 2018 May;115:119-124. doi: 10.1016/j.urology.2018.02.019. Epub 2018 Feb 27.

PMID:
29499258
12.

Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.

Petros FG, Metcalfe MJ, Yu KJ, Keskin SK, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG.

World J Urol. 2018 Jul;36(7):1093-1101. doi: 10.1007/s00345-018-2241-7. Epub 2018 Feb 27.

PMID:
29488096
13.

The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis.

Bhindi B, Wallis CJD, Boorjian SA, Thompson RH, Farrell A, Kim SP, Karam JA, Capitanio U, Golijanin D, Leibovich BC, Gershman B.

BJU Int. 2018 May;121(5):684-698. doi: 10.1111/bju.14127. Epub 2018 Mar 1. Review.

PMID:
29319926
14.

Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE.

Clin Genitourin Cancer. 2018 Apr;16(2):e443-e450. doi: 10.1016/j.clgc.2017.10.004. Epub 2017 Oct 17.

PMID:
29113770
15.

Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.

Han G, Zhao W, Song X, Kwok-Shing Ng P, Karam JA, Jonasch E, Mills GB, Zhao Z, Ding Z, Jia P.

BMC Genomics. 2017 Oct 3;18(Suppl 6):678. doi: 10.1186/s12864-017-4026-6.

16.

Editorial Comment.

Karam JA, Wood CG.

J Urol. 2018 Jan;199(1):52. doi: 10.1016/j.juro.2017.04.125. Epub 2017 Sep 22. No abstract available.

PMID:
28945990
17.

Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses.

Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, Matin SF, Wood CG, Karam JA.

J Urol. 2018 Feb;199(2):393-400. doi: 10.1016/j.juro.2017.09.072. Epub 2017 Sep 20.

PMID:
28941919
18.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

PMID:
28832979
19.

Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.

Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

J Endourol. 2017 Sep;31(9):946-953. doi: 10.1089/end.2016.0871. Epub 2017 Jul 21.

20.

Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response.

Ho TH, Choueiri TK, Wang K, Karam JA, Chalmers Z, Frampton G, Elvin JA, Johnson A, Liu X, Lin Y, Joseph RW, Stanton ML, Miller VA, Stephens PJ, Ross JS, Ali SM, Pal SK.

Eur Urol Focus. 2016 Jun;2(2):204-209. doi: 10.1016/j.euf.2015.11.007. Epub 2015 Dec 9.

PMID:
28723536
21.

Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy.

Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V.

J Urol. 2017 Dec;198(6):1269-1277. doi: 10.1016/j.juro.2017.06.096. Epub 2017 Jul 12.

PMID:
28709887
22.

The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma.

Chéry L, Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA.

Urology. 2017 Oct;108:114-121. doi: 10.1016/j.urology.2017.05.056. Epub 2017 Jul 10.

PMID:
28705573
23.

Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V.

J Urol. 2017 Dec;198(6):1253-1262. doi: 10.1016/j.juro.2017.06.086. Epub 2017 Jun 28.

PMID:
28668287
24.

Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.

Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Miller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH.

Eur Urol. 2018 Jan;73(1):71-78. doi: 10.1016/j.eururo.2017.05.033. Epub 2017 Jun 4.

PMID:
28592388
25.

Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.

Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X.

Cancer. 2017 Sep 15;123(18):3617-3627. doi: 10.1002/cncr.30707. Epub 2017 May 23.

26.

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.

Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM.

J Urol. 2017 Sep;198(3):530-537. doi: 10.1016/j.juro.2017.04.067. Epub 2017 Apr 11.

27.

Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.

Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, Lorentz CA, Bloom E, Bauman TM, Wood CG, Blute ML Jr.

J Urol. 2017 Oct;198(4):810-816. doi: 10.1016/j.juro.2017.04.066. Epub 2017 Apr 12.

28.

Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment.

Meyer CP, Sun M, Karam JA, Leow JJ, de Velasco G, Pal SK, Chang SL, Trinh QD, Choueiri TK.

Eur Urol. 2017 Aug;72(2):171-174. doi: 10.1016/j.eururo.2017.03.005. Epub 2017 Mar 27.

PMID:
28359734
29.

Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.

Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA.

J Urol. 2017 Aug;198(2):281-288. doi: 10.1016/j.juro.2017.03.011. Epub 2017 Mar 6.

PMID:
28268170
30.

Compartment Syndrome of the Hand: A Rare Sequela of Transradial Cardiac Catheterization.

Jue J, Karam JA, Mejia A, Shroff A.

Tex Heart Inst J. 2017 Feb 1;44(1):73-76. doi: 10.14503/THIJ-16-5795. eCollection 2017 Feb.

31.

Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.

Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C.

Ann Surg. 2018 Jul;268(1):172-178. doi: 10.1097/SLA.0000000000002195.

PMID:
28257320
32.

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.

Clin Genitourin Cancer. 2017 Jun;15(3):363-370. doi: 10.1016/j.clgc.2017.01.010. Epub 2017 Jan 18.

PMID:
28216278
33.

Nephrometry scoring systems: valuable research tools, but can they be applied in daily clinical practice?

Meissner MA, Karam JA.

BJU Int. 2017 Mar;119(3):364-365. doi: 10.1111/bju.13716. No abstract available.

34.

Co-chaperone Hsp70/Hsp90-organizing protein (Hop) is required for transposon silencing and Piwi-interacting RNA (piRNA) biogenesis.

Karam JA, Parikh RY, Nayak D, Rosenkranz D, Gangaraju VK.

J Biol Chem. 2017 Apr 14;292(15):6039-6046. doi: 10.1074/jbc.C117.777730. Epub 2017 Feb 13.

35.

MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity.

Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X.

Br J Cancer. 2017 Jan 3;116(1):77-84. doi: 10.1038/bjc.2016.392. Epub 2016 Dec 1.

36.

Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.

Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM.

Oncotarget. 2016 Dec 27;7(52):86280-86289. doi: 10.18632/oncotarget.13380.

37.

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.

Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM.

BJU Int. 2017 Dec;120(6):782-792. doi: 10.1111/bju.13705. Epub 2016 Dec 9.

PMID:
27860149
38.

Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study.

Abufaraj M, Moschini M, Soria F, Gust K, Özsoy M, Mathieu R, Rouprêt M, Margulis V, Karam JA, Wood CG, Briganti A, Bensalah K, Haitel A, Shariat SF.

World J Urol. 2017 Jul;35(7):1073-1080. doi: 10.1007/s00345-016-1968-2. Epub 2016 Nov 9.

39.

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV.

Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.

40.

Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract.

Wirth GJ, Haitel A, Moschini M, Soria F, Klatte T, Hassler MR, Bensalah K, Briganti A, Karam JA, Lotan Y, Margulis V, Raman JD, Remzi M, Rioux-Leclercq N, Robinson BD, Rouprêt M, Wood CG, Shariat SF.

World J Urol. 2017 Jun;35(6):943-949. doi: 10.1007/s00345-016-1946-8. Epub 2016 Oct 11.

PMID:
27730305
41.

Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial.

Kawakami F, Rao P, Tamboli P, Wood CG, Karam JA.

J Urol. 2017 Mar;197(3 Pt 1):559-565. doi: 10.1016/j.juro.2016.09.081. Epub 2016 Sep 25.

PMID:
27678298
42.

Cytoreductive nephrectomy for metastatic renal cell carcinoma.

Chery LJ, Karam JA, Wood CG.

Clin Adv Hematol Oncol. 2016 Sep;14(9):696-703. Review.

PMID:
27673288
43.

Biomarkers in Genitourinary Cancers: Blazing the Path Forward.

Pal SK, Karam JA, Chennamsetty A, Jones JO.

Eur Urol. 2017 Feb;71(2):247-248. doi: 10.1016/j.eururo.2016.09.011. Epub 2016 Sep 14. No abstract available.

PMID:
27639532
44.

Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma.

Pal SK, Karam JA, Bergerot P, Agarwal N.

J Clin Oncol. 2016 Nov 10;34(32):3825-3826. doi: 10.1200/JCO.2016.69.3572. No abstract available.

PMID:
27601540
45.

Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas.

Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B.

J Pathol Clin Res. 2015 Jul 7;1(4):212-24. doi: 10.1002/cjp2.23. eCollection 2015 Oct.

46.

HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).

Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Özsoy M, Remzi M, Gust KM, Shariat SF.

World J Urol. 2017 Feb;35(2):251-259. doi: 10.1007/s00345-016-1871-x. Epub 2016 Jun 7.

PMID:
27272502
47.

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.

Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM.

Clin Cancer Res. 2016 Dec 15;22(24):6236-6246. Epub 2016 Jun 2.

48.

Author reply.

Matin SF, Melquist J, Karam JA.

Urology. 2016 Jan;87:222-3. No abstract available.

PMID:
27243090
49.

Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract.

Raman JD, Warrick JI, Caruso C, Yang Z, Shuman L, Bruggeman RD, Shariat S, Karam JA, Wood C, Weizer AZ, Remzi M, Haitel A, Bensalah K, Rioux-Leclerq N, Bolenz C, Roscigno M, Krabbe LM, Kapur P, Lotan Y, Margulis V, DeGraff DJ.

Urology. 2016 Aug;94:314.e1-7. doi: 10.1016/j.urology.2016.05.030. Epub 2016 May 20.

50.

Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.

Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, Briganti A, Xylinas E, Shariat SF.

World J Urol. 2017 Jan;35(1):121-130. doi: 10.1007/s00345-016-1848-9. Epub 2016 May 21.

Supplemental Content

Loading ...
Support Center